Esophageal Cancer Clinical Trial
A Study of ERY974 in Patient With Advanced Solid Tumors
Summary
This is the open label, multicenter Phase 1 study which consists of a dose escalation to determine the maximum tolerated dose (MTD) and cohort expansion to obtain a preliminary evaluation of anti-tumor activity. ERY974 is intravenously injected to patients with Glypican 3 positive advanced solid tumors until unacceptable toxicity or disease progression.
Eligibility Criteria
Inclusion Criteria:
Male or female patient with Glypican 3 positive advanced solid tumor not amenable to standard therapy or for which standard therapy is not available or not indicated
Measurable tumor
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1
Adequate bone marrow, liver, and renal function
Adequate coagulation status
Exclusion Criteria:
Patients with more than a single brain metastasis ( >1 cm)
Patients with acute or chronic infection
Major surgery within 28 days
Pregnant or lactating women
Patients with interstitial pneumonitis
Patients require regular ascites/pleural effusion drainage
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Washington District of Columbia, , United States
Tampa Florida, , United States
Boston Massachusetts, , United States
Detroit Michigan, , United States
New York New York, , United States
Durham North Carolina, , United States
Providence Rhode Island, , United States
Paris , , France
Villejuif , , France
Groningen , , Netherlands
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.